## Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims.

## Listing of Claims:

- 1-40 (Canceled)
- (Currently amended) A method of inhibiting the activation or mobilization of eosinophils in an individual in need thereof comprising administering to said individual a therapeutically effective amount of a polypeptide consisting of an amino acid sequence shown in any one of SEQ4D NOs:23-144 the amino acid sequence of SEQ4D NOs:23-144 the acid sequence of S
- (Previously presented) The method of claim 1, wherein said polypeptide is fused to polyethylene glycol.
- (Previously presented) The method of claim wherein said polypeptide is fused to a heterologous polypeptide.
- 44-135 (Canceled)
- (Currently amended) A method of inhibiting the activation or mobilization of basophils in an individual in need thereof comprising administering to said individual a therapeutically effective amount of a polypeptide consisting of an amino acid sequence shown in any one of SEQ4D NOs:23-114 the amino acid sequence of SEQ4D NOs:23-114 the amino acid sequence of SEQ4D NOs:23-114 the
- (Previously presented) The method of claim 176, wherein said polypeptide is fused to polyethylene glycol.
- (Previously presented) The method of claim 126, wherein said polypeptide is fused to a heterologous polypeptide.
- 139-230 (Canceled)

- (New) A method of inhibiting the activation or mobilization of cosinophils in an individual in need thereof comprising administering to said individual a therapeutically effective amount of a polypeptide consisting of an amino acid sequence shown in any one of SEQ ID NOs:50, 51, 53, 94, 96, 97, and 99.
- 8 7. (New) The method of claim 221, wherein said polypeptide is fused to polyethylene glycol.
- (New) The method of claim 23, wherein said polypeptide is fused to a heterologous polypeptide.
- (New) The method of claim 227, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO.50.
- (New) The method of claim 237, wherein said polypeptide consists of the amino acid sequence of SFQ ID NO 51.
- 1226. (New) The method of claim 234, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO 53.
- (New) The method of claim 27, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO 94.
- The method of claim 24, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO 96.
- (New) The method of claim 21, wherein said polypeptide consists of the amino acid sequence of SEQ4D NO:97.

- (New) The method of claim 21, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:99.
- (New) A method of inhibiting the activation or mobilization of basophils in an individual in need thereof comprising administering to said individual a therapeutically effective amount of a polypeptide consisting of an amino acid sequence shown in any one of SEQ ID NOs:50, 51, 53, 94, 96, 97, and 99.
- (New) The method of claim 217, wherein said polypeptide is fused to polyethylene glycol.
- (New) The method of claim 24, wherein said polypeptide is fused to a heterologous polypeptide.
- (New) The method of claim 212, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:50.
- The method of claim 21, wherein said polypeptide consists of the amino acid sequence of SFQ ID NO:51.
- (New) The method of claim 241, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:53.
- (New) The method of claim 247, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:94.
- (New) The method of claim 217, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:96.
- 25 (New) The method of claim 247, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO.97.

26. (New) The method of claim 24, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:99.